Sanuwave Health Q2 2026 Earnings Report

Sanuwave Health EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.03
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Sanuwave Health Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $11.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sanuwave Health Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 7, 2026
• Conference Call Time: 8:30AM ET

Sanuwave Health (NASDAQ:SNWV), Inc. is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S. Food and Drug Administration for treatment of chronic diabetic foot ulcers. This portable, hand-held device provides a convenient alternative to conventional wound-care methods by delivering precision acoustic pulses directly to the affected tissue, thereby promoting neovascularization and reducing healing times. Sanuwave also supplies disposable treatment cartridges and related consumables to healthcare providers, and has established distribution agreements in North America and select overseas markets to broaden patient access.

Headquartered in Alpharetta, Georgia, Sanuwave Health originated as Tissue Regeneration Systems, Inc. before adopting its current name to reflect an expanded focus on regenerative medicine technologies. Under the leadership of Chief Executive Officer Jeff Bean, the company continues to advance its clinical research programs, pursue regulatory clearances for additional indications, and explore strategic partnerships. Sanuwave’s ongoing mission is to deliver innovative, non-invasive therapeutic solutions that improve patient outcomes and reduce healthcare costs worldwide.